Used in targeted cancer therapies, particularly for renal cell carcinoma and ovarian cancer, due to its specific binding to CDH6 (K-cadherin), a protein overexpressed in these tumor types. It serves as a key component in the development of antibody-drug conjugates (ADCs), enabling precise delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissues. Its high specificity and binding affinity make it valuable in diagnostic imaging and immunotherapeutic applications. Currently utilized in research and clinical settings to evaluate CDH6 expression and support the design of novel biologics.